

Images in urology – Metastatic urothelial carcinoma of the right vastus lateralis following robotic-assisted radical cystectomy

INTRODUCTION

Treatment for non-metastatic bladder cancer

Open radical cystectomy (ORC) is the gold standard for treating non-metastatic muscle-invasive bladder cancer (MIBC) (T2–T4a), as well as high-risk T1 disease.^{1,2} Although ORC remains the standard of care, recent meta-analyses have demonstrated no significant differences between ORC and robotic-assisted radical cystectomy (RARC) in regards to intraoperative and perioperative complication rates, as well as five-year recurrence-free survival, overall survival, and recurrence patterns.^{3,4} Recent systematic reviews have also demonstrated that RARC is not only a safe and effective procedure compared to laparoscopic radical cystectomy (LRC) and ORC, but also leads to lower rates of blood loss and transfusions.⁵

Metastasis following robotic-assisted surgery

Metastatic spread following robotic-assisted surgery (RAS) has been documented in several surgical subspecialties. Port site metastasis is rare but well-documented following laparoscopic and RAS for biliary, gynecologic, and urologic surgeries.^{6,7} In regards to metastasis following RARC, previous case reports have not only described port site metastasis, but also peritoneal carcinomatosis, extrapelvic lymph node involvement, and cutaneous metastasis.^{8,9} In this case report, we present an unusual metastasis following RARC for MIBC.

CASE REPORT

We present a 72-year-old male who was initially seen in consult for a persistently elevated prostate-specific antigen (PSA) with negative prostate biopsy. Magnetic resonance imaging (MRI) of the prostate demonstrated a Prostate Imaging–Reporting and Data System (PI-RADS) 2 prostate lesion with an incidental finding of two polypoid lesions along the right posterior bladder wall measuring 2.1 cm, highly suggestive of urothelial carcinoma.

Initial cystoscopy established presence of right posterior wall papillary tumors and transurethral resec-

Deron Britt, John Kim, Jennifer Tang, Chris Langley, Bobby Shayegan

Department of Urology, McMaster University, Hamilton, ON, Canada

Cite as: Britt D, Kim J, Tang J, et al. Images in urology – Metastatic urothelial carcinoma of the right vastus lateralis following robotic-assisted radical cystectomy (RARC). *Can Urol Assoc J* 2024;18(1):E37-9. <http://dx.doi.org/10.5489/cuaj.8431>

Published online September 29, 2023

tion of bladder tumor (TURBT) was performed. Initial pathology confirmed low-grade, non-invasive papillary carcinoma. The patient had multiple recurrences at the right lateral/posterior wall of the bladder, with persistent, low-grade pathology requiring repeat resection with TURBT and ongoing surveillance. His last followup cystoscopy demonstrated multiple bladder tumors along the right lateral wall and inter-trigone region. Repeat TURBT revealed high-grade, invasive papillary carcinoma with muscle invasion (cT2).

Preoperative computed tomography of the abdomen and pelvis identified a 5.4 cm bladder mass located at the bladder dome, suggestive of submucosal/mural recurrence at previous resection sites, and a single indeterminate right external iliac lymph node. Therefore, initial staging was described as cT3N0 (query N1) M0. The patient underwent four cycles of neoadjuvant cisplatin and gemcitabine in preparation for cystectomy. This was followed by RARC with bilateral pelvic lymph node dissection and intracorporeal orthotopic ileal neobladder substitution.

Final pathology demonstrated high-grade, muscle-invasive urothelial carcinoma with macroscopic extravescical extension, negative margins, and one out of 27 positive regional lymph nodes (pT3bN1M0). Six months postoperatively the patient presented for followup with persistent right leg pain. MRI of the right femur demonstrated a single soft tissue mass measuring 5.7 cm within the right vastus lateralis (Figure 1). This was biopsied and proved to be metastatic high-grade urothelial carcinoma.

Followup CT of the chest, abdomen, and pelvis (CAP) demonstrated abnormal sclerosis and remodeling of the right third rib, as well as mildly enhancing bilateral inguinal nodes that were possibly metastatic in nature. A nuclear medicine (NM) bone scan revealed




Figure 1. Magnetic resonance imaging of the right femur demonstrating large soft tissue mass at junction of vastus lateralis/intermedialis in (A) sagittal; and (B) transverse view.

a hyperemic mass in the lateral aspect of the right thigh with increased bony uptake in the right femur, as well as an additional lesion in the left iliac wing.

Palliative combination chemotherapy was initiated with cisplatin/gemcitabine followed by carboplatin/gemcitabine therapy. Followup NM bone scan following chemotherapy treatment demonstrated slight progression of the right thigh mass and repeat CT CAP showcased a new 2.2 cm left iliac wing lesion not seen on previous imaging. Patient was started on intravenous pembrolizumab and, at the time of followup appointment after two cycles, stated that pain symptoms were well-controlled and that he was tolerating treatment well, with manageable pruritus on right leg.

DISCUSSION

At this time, known metastatic sites following ORC have previously involved lymph nodes, bone, lung, liver, and peritoneum, whereas documentation of metastasis following RARC has been less exhaustive.^{10,11} A recent systematic review showcased a 1.63% incidence of atypical recurrence following RARC.¹² Of these cases (63 of the 105 atypical recurrences), 60% involved peritoneal carcinomatosis, 15.2% involved extrapelvic lymph node metastasis, 10.5% involved port-site metastasis, 9.5% involved retroperitoneal nodal disease, and 3.8% involved multiple atypical recurrences.¹³

Although the growing evidence demonstrating the safety and efficacy of RARC lends support to its growing popularity, there remain ongoing concerns regarding the documented risk of atypical tumor recurrences associated with laparoscopic and RAS.¹⁴ While the exact

mechanism by which these approaches increase the risk of atypical metastasis is unclear, previous reports have proposed that the insufflation and subsequent reduction of pneumoperitoneum that is required in laparoscopic abdominopelvic surgery may promote tumor seeding via aerosolization of remnant tumor cells.¹² Based on this potential mechanism, factors that may influence the risk of atypical recurrence during laparoscopic or RAS include the flow and pressure settings, the distance between the inflow trocar and the tumor, and the stability of the pneumoperitoneum.¹⁵ While these variables may impact the risk of tumor spread within the abdominal and pelvic cavities, they do not provide an explanation for distant recurrence outside of the abdomen and pelvis, such as that seen within this case report.

Further investigation is required to determine what risk factors might contribute to distant extrapelvic recurrence.

CONCLUSIONS

To our knowledge, this case report is the first to describe distant soft tissue recurrence of urothelial carcinoma of the bladder following RARC and highlights the oncologic risks specific to this increasingly popular procedure. Though rare and poorly understood, the potential for atypical recurrences occurring after RAS should be addressed preoperatively so that patients can acquire a more complete understanding of the risks associated with novel uro-oncologic procedures.

COMPETING INTERESTS: Dr. Shayegan has received grants/honoraria from Abbvie, Astellas, Bayer, Janssen, Knight, Pfizer, TerSera, and Tolmar; and participated in the CREST study supported by Pfizer. All other authors report no competing personal or financial interests related to this work.

This paper has been peer-reviewed.

REFERENCES

- Maibom SL, Joensen UN, Poulsen AM, et al. Short-term morbidity and mortality following radical cystectomy: A systematic review. *BMJ Open* 2021;11:1-12. <https://doi.org/10.1136/bmjopen-2020-043266>
- Mari A, Campi R, Tellini R, et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: A comprehensive review of the literature. *World J Urol* 2018;36:157-70. <https://doi.org/10.1007/s00345-017-2115-4>
- Satkunasivam R, Tallman CT, Taylor JM, et al. Robot-assisted radical cystectomy versus open radical cystectomy: A meta-analysis of oncologic, perioperative, and complication-related outcomes. *Eur Urol Oncol* 2019;2:443-7. <https://doi.org/10.1016/j.euo.2018.10.008>
- Chade DC, Laudone VP, Bochner BH, et al. Oncological outcomes after radical cystectomy for bladder cancer: Open vs. minimally invasive approaches. *J Urol* 2010;183:862-70. <https://doi.org/10.1016/j.juro.2009.11.019>
- Novara G, Catto JW, Wilson T, et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. *Eur Urol* 2015;67:376-401. <https://doi.org/10.1016/j.eururo.2014.12.007>
- Liu Q D, Chen JZ, Xu XY, et al. Incidence of port-site metastasis after undergoing robotic surgery for biliary malignancies. *World J Gastroenterol* 2012;18:5695. <https://doi.org/10.3748/wjg.v18.i40.5695>

7. Rindos N, Curry CL, Tabbarah R, et al. Port-site metastases after robotic surgery for gynecologic malignancy. *JSL* 2014;18:66. <https://doi.org/10.4293/108680813X13693422519271>
8. Yajima S, Nakanishi Y, Wantanabe R, et al. Urothelial carcinoma of the bladder with cutaneous metastases after robot-assisted radical cystectomy. Case report. *Urol Case Rep* 2021;38:101709. <https://doi.org/10.1016/j.eucr.2021.101709>
9. Audenet F, Sfakianos JP. Evidence of atypical recurrences after robot-assisted radical cystectomy: A comprehensive review of the literature. *Bladder Cancer* 2017;3:231-6. <https://doi.org/10.3233/BLC-170127>
10. Ghoneim MA, Abdel-Latif M, El-Mekresh M, et al. Radical cystectomy for carcinoma of the bladder: 2720 consecutive cases 5 years later. *J Urol* 2008; 180:121-7. <https://doi.org/10.1016/j.juro.2008.03.024>
11. Shinagare AB, Ramaiya NH, Jagannathan JP, et al. Metastatic pattern of bladder cancer: Correlation with the characteristics of the primary tumor. *AJR Am J Roentgenol* 2011;196:117-22. <https://doi.org/10.2214/AJR.10.5036>
12. Kiss B, Burkhard FC, Thalmann GN. Open radical cystectomy: Still the gold standard for muscle-invasive bladder cancer. *World J Uro* 2016;34:33-9. <https://doi.org/10.1007/s00345-015-1729-7>
13. Mantica G, Smelzo S, Ambrosini F, et al. Port-site metastasis and atypical recurrences after robotic-assisted radical cystectomy (RARC): An updated comprehensive and systematic review of current evidences. *J Robot Surg* 2020; 14:805-12. <https://doi.org/10.1007/s11701-020-01062-x>
14. Hussein AA, Saar M, May PR, et al. Early oncologic failure after robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol* 2017;197:1427-36. <https://doi.org/10.1016/j.juro.2016.12.048>
15. Galloli A, De Lorenzis E, Lievore E, et al. The effect of CO₂ pressure and flow variation on carbon particles spread during pneumoperitoneum: An experimental study. *J Endourol* 2022;36:807-13. <https://doi.org/10.1089/end.2021.0336>

CORRESPONDENCE: Dr. Deron Britt, Department of Urology, McMaster University, Hamilton, ON, Canada; deron.britt@medportal.ca